

## **EMMESSAR BIOTECH & NUTRITION LTD**

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001 Tel: 022-49738167/68 Email: <a href="mailto:enquiries@ebnl.org">enquiries@ebnl.org</a> Site: <a href="mailto:www.ebnl.org">www.ebnl.org</a> Investors Grievance Email: <a href="mailto:investors@ebnl.org">investors@ebnl.org</a> CIN No. L24110MH1992PLC065942

EBN/2019/S-2449

February 5, 2019

Mr. S. Subramanian, DCS - CRD
The Stock Exchange, Mumbai
Phiroze Jeejebhoy Towers, 2<sup>nd</sup> floor
Dalal Street, Fort, Mumbai – 400 001,

Dear Sir,

Sub: Filing of the advertisement copies of the Unaudited Financial Results.

Ref: Company Code No. 524768

Pursuant to Regulation 47 of the SEBI [LODR] Regulations 2015, please find attached the copies of newspaper publication of Unaudited Financial Results for the quarter / Nine months ended December 31, 2018, published in Free Press Journal and Nav Shakti on Tuesday, February 5, 2019.

You are kindly requested to take the above on your records.

MUMBA

Thanking you,

Yours faithfully, For Emmessar Biotech & Nutrition Ltd

Compliance Officer

Encl: As above



## **Emmessar Biotech & Nutrition Ltd.**

Registered Office: Plot No.T-3/2, MIDC, Taloja, Raigad Dist., Maharashtra - 410 208. CIN: L24110MH1992PLC06594229

### **UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2018**

(₹ in lakhs)

ILTANCY]	CONS		Unaudited	emacual and	e di pathi	Audited year
Particulars ACCUT NAVALA	MISSE	Quarter Ende	ed	9 months	ended m	
	31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
I) Revenue from Operations	28.38	5.44	12.76	. 47.68	121.50	131.50
II) Other Income	31.58	31.53	31.68	94.13	94.06	126.55
III) Total Income (I + II)	59.96	36.97	44.44	141.81	215.56	258.05
IV) Expenses						
Cost of material consumed	0.81	1.27	0.50	3.89	39.25	40.63
Excise duty on sale of goods	-	-			-	6.20
Purchase of Stock-trade	6.15		2.89	10.65	10.28	10.28
Change in Inventories of Finished goods	3.85	1.47	1.87	* 3.92	12.33	11.69
Employee Benefit Expenses	16.14	20.25	12.42	46.97	31.30	40.76
Depreciation & Amortisation of Assets	2.15	2.15	1.84	6.46	2.42	5.06
Other Expenditure	13.35	7.76	5.55	30.58	53.13	63.83
Total Expenses (IV)	42.45	32.90	25.07	102.47	148.71	178.45
V) Profit / (loss) from Operations before tax (III - IV)	17.51	4.07	19.37	39.34	66.85	- 79.60
VI) Exceptional Items	-		10.16			0.00
VII) Profit / (loss) before Tax	-					79.54
VIII) Tax Expenses						
1. Current Tax (MAT)	-					(22.00
2. Deferred Tax						33.75
IX) Net Profit / (loss) after tax (V - VI)	17.51	4.07	19.37	39.34	66.85	91.29
X) Other Comprehensive Income	-	7	-			1.8
XI) Total comprehensive income and						
Other Comprehensive Income	17.51	4.07	19.37	39.34	66.85	89.4
XII) Paid-up Equity Share Capital	499.61	499.61	499.61	499.61	499.61	499.6
(Face Value of the share)	10.00	10.00	10.00	10.00	10.00	10.00
Earning per Share						
- Basic	0.35	0.08	0.39	0.79	1.34	1,79
Diluted	0.35	0.08	0.39	0.79	1.34	1.79

#### Notes

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards (IND AS-34 Interim Financial Reporting) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Amendment Rules, 2016 as amended therafter.
- 2 The above financial results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 2nd Feb 2019 and have been subjected to Limited Review by the Statutory Auditors.
- 3 The limited review as required under Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 has been completed by the Auditors of the Company.
- 4 The Company operates two segment i.e. Healthcare and rent on leasehold land during this quarter.
- 5 The Government of India has implemented Goods and Services Tax (GST) w.e.f 1st July 2017 which replaces excise duty and various other indirect taxes. As per Ind AS sales for the quarter and nine months ended 31st Dec-2018, quarter ended 30th Sep-2018, quarter ended 30th June 2018, December 2017 and Sept-2017 are reported net of GST. The year ended 31st Mar-2018 and six months ended 30th Sep-2017 includes excise duty upto June 2017.
- 6 Deferred tax & provision for taxation will be calculated annually.
- 7 One Investor Complaint was received and the same was disposed off during the quarter ended 31st Dec 2018

# Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 31st Dec 2018

	O THE CONTRACT OF THE CONTRACT						
Particulars		Quarter Ende	ed	9 months p	Year Ended		
	31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018	
1. Segment Revenue							
a. Healthcare	28.38	5.44	12.76	47.68	36.84	40.61	
b. Fine Chemicals	-	0.00		-	84.65	84.68	
c. Rent on leasehold land	30.71	30.71	30.72	. 92.13	92.13	122.85	
d Others	0.87	0.82	0.96	2.00	1.89	3.70	
Total:	59.96	36.97	44.44	141.81	215.51	251.84	
Less: Inter Segment Revenue						-	
Net Sales / Income from Operations	59.96	36.97	44.44	141.81	215.51	251.84	
2. Segment Results (Profit / Loss)							
before tax							
a. Healthcare	17.23	2.36	8.00	28.08	12.32	22.09	
b. Fine Chemicals	- 19	-	4		5.49	6.12	
c. Rent on leasehold land	30.29	30.29	30.30	90.87	90.87	122.85	
d. Others	0.87	0.82	0.96	2.00	1.89	3.70	
Total:	48.39	33.47	39.26	120.95	110.57	154.76	
Less:	10 × 10 10 6						
Interest	-		-	-	-	1	
Other Unallocable Expenditure (net off)	30.88	29.40	19.89	81.61	43.73	75.17	
Total Profit before Tax	17.51	4.07	19.37	39.34	66.84	79.59	
3. Capital Employed							
(Segment Assets - Segment Liabilities)						7	
a. Healthcare	6.43	11.32	2.62	6.43	2.62	12.04	
b. Fine Chemicals	72.99	69.07	58.74	72.99	58.74	58.74	
c. Rent on leasehold land	2.46	3.30	4.56	2.46	4.56	65.37	
d. Others	210.48	237.04	186.82	210.48	186.82	203.63	
Total:	292.36	320.73	252.74	292.36	252.74	339.78	



# **Emmessar Biotech & Nutrition Ltd.**

Registered Office: Plot No.T-3/2, MIDC, Taloja, Raigad Dist., Maharashtra - 410 208. CIN: L24110MH1992PLC06594229

## UNAUDITED FINANCIAL RESULTS AS ON 31st DECEMBER 2018

(₹ in lakhs)

2088

	300	Audited year				
Particulars		Quarter Ende	d	9 months period Ended		ended
	31.12.2018	30.09.2018	31,12,2017	31.12.2018	31.12.2017	31.03.2018
	STATE OF THE PARTY	5.44	12.76	47.68	121.50	131.50
Revenue from Operations	28.38	31.53	31.68	94.13	94.06	126.55
Other Income	31.58	36.97	44.44	141.81	215.56	258.05
i) Total Income (I + II)	59.96	30.97			1-1-12-10	
) Expenses	0.00	1.27	0.50	3.89	39.25	40.63
Cost of material consumed	0.81	1.27	0.50		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	6.20
Excise duty on sale of goods	-		2.89	10.65	10.28	10.28
Purchase of Stock-trade-	6.15	1.47	1.87	3.92	12.33	11.69
Change in Inventories of Finished goods	3.85	20.25	12.42	46.97	31,30	40.76
Employee Benefit Expenses	16.14	20.25	1.84	6.46	2.42	5.06
Depreciation & Amortisation of Assets	2.15	THE PERSON NAMED IN	5.55	30.58	53.13	63.83
Other Expenditure	13.35	7.76	25.07	102.47	148.71	178.4
Total Expenses (IV)	42.45	32.90	19.37	39.34	66.85	
/) Profit / (loss) from Operations before tax (III - IV	17.51	4.07	19.57	37.57		0.00
/I) Exceptional Items					2-	79.5
/II) Profit / (loss) before Tax						1300
VIII) Tax Expenses			Contract of the Contract of th			(22.00
1. Current Tax (MAT)					2	33.7
2. Deferred Tax	1 2 2 3	4.07	19.37	39.34	66.8	5 91.2
IX) Net Profit / (loss) after tax (V - VI)	17.51	4.07	19.37	33.37		1.8
X) Other Comprehensive Income						
XI) Total comprehensive income and			19.37	39.34	66.8	5 89.4
Other Comprehensive Income	17.51				499.6	
XII) Paid-up Equity Share Capital	499.61			COLUMN TO SERVICE SERV	10.0	
(Face Value of the share)	10.00	10.00	10.00	10.00	10.0	
Earning per Share			3 0.39	0.79	1.3	4 1.
Basic	0.35		AND DESCRIPTION OF THE PERSON	AND RESIDENCE AND ADDRESS OF THE PARTY NAMED IN COLUMN TWO IS NOT THE PARTY NAMED IN COLUMN TWIND TWO IS NOT THE PARTY NAMED IN COLUMN TWO IS NOT THE PARTY NAM	The second second	PART SECTION SECTION
Diluted	0.35	0.08	3 0.3	0.79	1.5	

- 1 The above financial results have been prepared in accordance with Indian Accounting Standards (IND AS-34 Interim Financial Reporting) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Amendment Companies (Indian Accounting Standards) Amendment Rules, 2016 as amended therafter.
- 2 The above financial results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 2nd Feb 2019 and have been subjected to Limited Review by the Statutory Auditors.
- 3 The limited review as required under Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements)
  Regulations 2015 has been completed by the Auditors of the Company.
- 4 The Company operates two segment i.e. Healthcare and rent on leasehold land during this quarter.
- The Company operates two segment re. realurcare and rent on leasenoid rand during this quarter.

  The Government of India has implemented Goods and Services Tax (GST) w.e.f 1st July 2017 which replaces excise duty and various other indirect taxes. As per Ind AS sales for the quarter and nine months ended 31st Dec-2018, quarter ended 30th Sep-2018, quarter ended 30th Sep-2017 and Sept-2017 are reported net of GST. The year ended 31st Mar-2018 and six months ended 30th Sep-2017 includes excise duty upto June 2017.
- 6 Deferred tax & provision for taxation will be calculated annually
- 7 One Investor Complaint was received and the same was disposed off during the quarter ended 31st Dec 2018

## Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 31st Dec 2018 (₹ in lakhs)

1		Audited				
Particulars		Quarter Ende	d	9 months period Ended		Year Ended
	31.12.2018	30.09.2018	31.12.2017	31.12.2018	31.12.2017	31.03.2018
a. Healthcare b. Fine Chemicals c. Rent on leasehold land d Others	28.38 30.71 0.87 <b>59.96</b>	5.44 0.00 30.71 0.82 <b>36.97</b>	12.76 30.72 0.96 44.44	47.68 92.13 2.00 141.81	36.84 84.65 92.13 1.89 215.51	40.61 84.68 122.85 3.70 251.84
Total: Less: Inter Segment Revenue Net Sales / Income from Operations	59.96	36.97	44.44	141.81	215.51	251.84
Segment Results (Profit / Loss) before tax a. Healthcare b. Fine Chemicals c. Rent on leasehold land d. Others Total:	17.23 30.29 0.87 48.39	2.36 30.29 0.82 33.47	8.00 30.30 0.96 <b>39.26</b>	28.08 90.87 2.00 120.95	12.32 5.49 90.87 1.89	22.09 6:12 122.85 3.70 <b>154.76</b>
Less: Interest Other Unallocable Expenditure (net off	30.88	29.40 · <b>4.07</b>	19.89 19.37	81.61 39.34	43.73	
3. Capital Employed (Segment Assets - Segment Liabilities a. Healthcare b. Fine Chemicals c. Rent on leasehold land d. Others Total:	6.43 72.99 2.46 210.48	11.32 69.07 3.30 237.04	2.62 58.74 4.56 186.82	6.43 72.99 2.46 210.48 <b>292.36</b>	4.56 186.83	58.74 65.37 2 203.63

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.
The above results were taken on record at a meeting of the Board of Directors held on 2nd February, 2019.

By order of the Board
MSR Ayyangar
Managing Director